Moderna's Massive Run Cools Off While the MACD Flashes a Warning

Moderna is still crushing the S&P 500 over three months, but a bearish MACD cross and thin volume suggest the easy gains are behind it for now.

Trend
long-term uptrend, short-term pullback
Support
182.50, then 133.33
Resistance
254.48 (52-week high)
Invalidation
daily close below 182.50 support

Relative Strength: No Contest, But the Gap Is Narrowing

Measured against the broad market, Moderna isn't in the same conversation as the S&P 500 lately, it's in a different league entirely. Over three months, MRNA is up 272.25% while the S&P 500 (SPY) has gained a respectable but pedestrian 3.99%. Even over the past month the stock is ahead, up 5.97% versus the index's 0.92%.

But zoom into the last five sessions and the story flips. Moderna has dropped 12.29% over that stretch while the S&P 500 is basically flat, down just 0.24%. That's a sharp reversal in short-term relative strength, and it's worth paying attention to even though the longer-term trend still favors the stock by a wide margin.

Trend and Moving Averages

As of the close on October 28, 2026, Moderna sits at $215.61, up 3.67% on the day. The stock remains in a technical uptrend: price is above a rising 50-day moving average ($179.78), and the 50-day is above the 200-day ($84.77). That's about as textbook bullish as a long-term structure gets, and the stock is 19.93% above its 50-day and a staggering 154.36% above its 200-day.

That said, the 200-day distance is a reminder of just how far this move has already traveled. Price is sitting just above its 20-day average of $211.94, which is the first line of support the bulls need to hold.

Momentum: RSI Neutral, MACD Rolling Over

RSI14 reads 55.5, which is neutral territory, neither overbought nor oversold. That's actually a notable cooling off given the size of the three-month advance.

The MACD is the bigger flag here. MACD sits at 10.84, below its signal line at 15.31, producing a negative histogram reading of -4.47. The fact sheet confirms a bearish MACD crossover within the last five sessions. That lines up with the five-day pullback and suggests momentum is fading even as the broader trend stays intact.

Volume Tells a Quiet Story

Volume came in at 8,264,564 shares, only 0.42 times the 20-day average. That's thin participation on a day where the stock bounced 3.67%. A bounce on light volume carries less conviction than one backed by heavy trading, so this rally attempt should be watched for confirmation rather than taken as a sign sellers have been overrun.

Levels That Matter

Support sits at $182.50, with a deeper floor at $133.33. On the upside, the 52-week high at $254.48 is the key resistance, with the stock currently 15.27% below that mark after the recent pullback from levels near $245.81 just a few sessions ago.

A close that reclaims the 20-day average near $211.94 and pushes back above the recent swing highs would support the idea that the pullback was just a shakeout within the larger uptrend. A break below the $182.50 support level, on the other hand, would call the near-term structure into question and open the door toward the $133.33 zone. With ATR14 at $24.82 (11.51% of price), this stock continues to move in wide, fast swings, so position sizing should account for that volatility either way.

This article was produced with the help of AI from market data as of October 28, 2026, 2:00 PM ET (intraday), using rules that limit it to the numbers in that data. It may still contain errors. It is for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Technical analysis describes past price behavior and does not predict future results. Do your own research and consult a licensed advisor. See our full disclaimer.